Novel Matrixyl-Derived Lipopeptide C16KTTβAH Selectively Kills Breast Cancer Cells and Forms High-Modulus Hydrogels
Background
Peptide-based biomaterials are a major area of research due to their biocompatibility and potential for therapeutic applications. Specifically, self-assembling peptides that can form hydrogels are sought after for drug delivery, tissue engineering, and direct therapeutic action. Lipopeptides, which combine a peptide sequence with a lipid chain, often exhibit enhanced self-assembly properties. This study focuses on designing a novel lipopeptide by combining a sequence from the well-known "Matrixyl" family of cosmetic peptides (KTT) with the bioactive carnosine dipeptide (βAH). The goal is to create a multi-functional material that not only possesses unique physical properties like hydrogel formation but also exhibits targeted biological activity, such as selective anti-cancer effects, a significant challenge in oncology.
Study Design
Researchers designed and synthesized a novel lipopeptide, C16KTTβAH, by attaching a hexadecyl (C16) lipid chain to a peptide sequence containing the KTT tripeptide from Matrixyl and the βAH dipeptide from carnosine. They investigated its self-assembly properties in water, phosphate-buffered saline (PBS), and cell culture media, measuring the critical aggregation concentration. They used imaging techniques to visualize the resulting nanostructures. The anti-cancer activity of C16KTTβAH was assessed in vitro using two model breast cancer cell lines (MCF-7) and two fibroblast cell line controls to determine selective cytotoxicity. Finally, the hydrogels formed by the lipopeptide were tested for their ability to absorb and release the model diagnostic compound Congo red.
Results
The lipopeptide C16KTTβAH self-assembles into β-sheet nanotape structures above a critical aggregation concentration. In PBS, these nanotapes form bundles, leading to hydrogelation. These hydrogels demonstrated tunable stiffness based on concentration and aqueous conditions, with direct dissolution in PBS creating stiff gels. Furthermore, injecting dilute aqueous solutions into PBS produced hydrogels with exceptionally high modulus compared to previously reported β-sheet peptide materials. The peptide also showed selective, concentration-dependent cytotoxicity against MCF-7 breast cancer cells in the mM concentration range.
Importantly, this cytotoxic effect occurred below the critical aggregation concentration, indicating that the anti-cancer activity is an intrinsic property of the individual lipopeptide molecules, not a result of their self-assembled structures. The resulting hydrogels also demonstrated the ability to slowly uptake and release the model dye, Congo red.
Key Findings
- The lipopeptide C16KTTβAH self-assembles into β-sheet nanotape structures in various aqueous media.
- Hydrogels formed by injecting dilute C16KTTβAH solutions into PBS have an unprecedentedly high modulus for β-sheet peptides.
- C16KTTβAH exhibits selective, concentration-dependent cytotoxicity against MCF-7 breast cancer cells.
- Cytotoxicity occurs in the mM concentration range and below the peptide's critical aggregation concentration.
- The hydrogels demonstrate slow uptake and release of the model diagnostic compound Congo red.
Why It Matters
This research introduces a multi-functional biomaterial with dual properties: a potent, self-assembling hydrogel and a selective anti-cancer agent. For researchers and developers in the peptide space, this demonstrates a powerful design principle of combining known bioactive fragments (from Matrixyl and carnosine) to create novel molecules with emergent properties. The exceptional stiffness of the hydrogels could make them superior scaffolds for tissue engineering or controlled-release depots. The key takeaway is that the peptide's cancer-killing ability is separate from its gelling ability, suggesting it could be used as a soluble therapeutic agent or as a drug-eluting, anti-cancer hydrogel for localized treatment. This is a preclinical, in vitro finding, and significant further research is needed to explore its in vivo efficacy, safety, and delivery mechanisms before any clinical translation could be considered.
peptide
lipopeptide
matrixyl
carnosine
in vitro
hydrogel